215 related articles for article (PubMed ID: 23663038)
21. Fine Mapping of a Dravet Syndrome Modifier Locus on Mouse Chromosome 5 and Candidate Gene Analysis by RNA-Seq.
Hawkins NA; Zachwieja NJ; Miller AR; Anderson LL; Kearney JA
PLoS Genet; 2016 Oct; 12(10):e1006398. PubMed ID: 27768696
[TBL] [Abstract][Full Text] [Related]
22. A novel rat model of Dravet syndrome recapitulates clinical hallmarks.
Li M; Yang L; Qian W; Ray S; Lu Z; Liu T; Zou YY; Naumann RK; Wang H
Neurobiol Dis; 2023 Aug; 184():106193. PubMed ID: 37295561
[TBL] [Abstract][Full Text] [Related]
23. Developmental alterations in firing properties of hippocampal CA1 inhibitory and excitatory neurons in a mouse model of Dravet syndrome.
Almog Y; Fadila S; Brusel M; Mavashov A; Anderson K; Rubinstein M
Neurobiol Dis; 2021 Jan; 148():105209. PubMed ID: 33271326
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological characterization of an antisense knockdown zebrafish model of Dravet syndrome: inhibition of epileptic seizures by the serotonin agonist fenfluramine.
Zhang Y; Kecskés A; Copmans D; Langlois M; Crawford AD; Ceulemans B; Lagae L; de Witte PA; Esguerra CV
PLoS One; 2015; 10(5):e0125898. PubMed ID: 25965391
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms contributing to the exacerbated epileptiform activity in hippocampal slices expressing a C-terminal truncated GABA(B2) receptor subunit.
Thuault SJ; Brown JT; Calver AR; Collingridge GL; Randall A; Davies CH
Epilepsy Res; 2005 Jun; 65(1-2):41-51. PubMed ID: 15979855
[TBL] [Abstract][Full Text] [Related]
26. Proteomic signature of the Dravet syndrome in the genetic Scn1a-A1783V mouse model.
Miljanovic N; Hauck SM; van Dijk RM; Di Liberto V; Rezaei A; Potschka H
Neurobiol Dis; 2021 Sep; 157():105423. PubMed ID: 34144125
[TBL] [Abstract][Full Text] [Related]
27. Antisense oligonucleotides restore excitability, GABA signalling and sodium current density in a Dravet syndrome model.
Yuan Y; Lopez-Santiago L; Denomme N; Chen C; O'Malley HA; Hodges SL; Ji S; Han Z; Christiansen A; Isom LL
Brain; 2024 Apr; 147(4):1231-1246. PubMed ID: 37812817
[TBL] [Abstract][Full Text] [Related]
28. Electroencephalographic features of patients with SCN1A-positive Dravet syndrome.
Lee HF; Chi CS; Tsai CR; Chen CH; Wang CC
Brain Dev; 2015 Jun; 37(6):599-611. PubMed ID: 25459968
[TBL] [Abstract][Full Text] [Related]
29. Variability of EEG-fMRI findings in patients with SCN1A-positive Dravet syndrome.
Moehring J; von Spiczak S; Moeller F; Helbig I; Wolff S; Jansen O; Muhle H; Boor R; Stephani U; Siniatchkin M
Epilepsia; 2013 May; 54(5):918-26. PubMed ID: 23398550
[TBL] [Abstract][Full Text] [Related]
30. Role of the hippocampus in Nav1.6 (Scn8a) mediated seizure resistance.
Makinson CD; Tanaka BS; Lamar T; Goldin AL; Escayg A
Neurobiol Dis; 2014 Aug; 68():16-25. PubMed ID: 24704313
[TBL] [Abstract][Full Text] [Related]
31. Preferential inactivation of Scn1a in parvalbumin interneurons increases seizure susceptibility.
Dutton SB; Makinson CD; Papale LA; Shankar A; Balakrishnan B; Nakazawa K; Escayg A
Neurobiol Dis; 2013 Jan; 49():211-20. PubMed ID: 22926190
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of stiripentol in hyperthermia-induced seizures in a mouse model of Dravet syndrome.
Cao D; Ohtani H; Ogiwara I; Ohtani S; Takahashi Y; Yamakawa K; Inoue Y
Epilepsia; 2012 Jul; 53(7):1140-5. PubMed ID: 22578034
[TBL] [Abstract][Full Text] [Related]
33. Sleep impairment and reduced interneuron excitability in a mouse model of Dravet Syndrome.
Kalume F; Oakley JC; Westenbroek RE; Gile J; de la Iglesia HO; Scheuer T; Catterall WA
Neurobiol Dis; 2015 May; 77():141-54. PubMed ID: 25766678
[TBL] [Abstract][Full Text] [Related]
34. Modeling NaV1.1/SCN1A sodium channel mutations in a microcircuit with realistic ion concentration dynamics suggests differential GABAergic mechanisms leading to hyperexcitability in epilepsy and hemiplegic migraine.
Lemaire L; Desroches M; Krupa M; Pizzamiglio L; Scalmani P; Mantegazza M
PLoS Comput Biol; 2021 Jul; 17(7):e1009239. PubMed ID: 34314446
[TBL] [Abstract][Full Text] [Related]
35. Impaired excitability of somatostatin- and parvalbumin-expressing cortical interneurons in a mouse model of Dravet syndrome.
Tai C; Abe Y; Westenbroek RE; Scheuer T; Catterall WA
Proc Natl Acad Sci U S A; 2014 Jul; 111(30):E3139-48. PubMed ID: 25024183
[TBL] [Abstract][Full Text] [Related]
36. Convulsive seizures and some behavioral comorbidities are uncoupled in the Scn1a
Fadila S; Quinn S; Turchetti Maia A; Yakubovich D; Ovadia M; Anderson KL; Giladi M; Rubinstein M
Epilepsia; 2020 Oct; 61(10):2289-2300. PubMed ID: 32865826
[TBL] [Abstract][Full Text] [Related]
37. A selective Na
Chow CY; Chin YKY; Ma L; Undheim EAB; Herzig V; King GF
Biochem Pharmacol; 2020 Nov; 181():113991. PubMed ID: 32335140
[TBL] [Abstract][Full Text] [Related]
38. Insights into pathophysiology and therapy from a mouse model of Dravet syndrome.
Oakley JC; Kalume F; Catterall WA
Epilepsia; 2011 Apr; 52 Suppl 2(Suppl 2):59-61. PubMed ID: 21463282
[TBL] [Abstract][Full Text] [Related]
39. Upregulation of Haploinsufficient Gene Expression in the Brain by Targeting a Long Non-coding RNA Improves Seizure Phenotype in a Model of Dravet Syndrome.
Hsiao J; Yuan TY; Tsai MS; Lu CY; Lin YC; Lee ML; Lin SW; Chang FC; Liu Pimentel H; Olive C; Coito C; Shen G; Young M; Thorne T; Lawrence M; Magistri M; Faghihi MA; Khorkova O; Wahlestedt C
EBioMedicine; 2016 Jul; 9():257-277. PubMed ID: 27333023
[TBL] [Abstract][Full Text] [Related]
40. A functional null mutation of SCN1B in a patient with Dravet syndrome.
Patino GA; Claes LR; Lopez-Santiago LF; Slat EA; Dondeti RS; Chen C; O'Malley HA; Gray CB; Miyazaki H; Nukina N; Oyama F; De Jonghe P; Isom LL
J Neurosci; 2009 Aug; 29(34):10764-78. PubMed ID: 19710327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
